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In the early 1970s, camptothecin, a plant alkaloid
extract from the bark and wood of the Chinese tree
Camptotheca acuminata, was shown to possess anti-
neoplastic activity.1 Analogs of camptothecin belong to
a family of anticancer agents with a unique mechanism
of action that is based on reversible inhibition of DNA
topoisomerase I.2,3
Despite the cytotoxicity of the compound, further
development was halted because of a number of severe
and unpredictable side effects observed in early clini-
cal trials.4-6 The subsequent search for less toxic
analogs of camptothecin resulted in the discovery of
irinotecan, topotecan, 9-amino-20(S)-camptothecin, 9-
nitrocamptothecin, DX-8951f, and GI147211. The first
two—irinotecan and topotecan—were recently regis-
tered for the treatment of colorectal and ovarian can-
cer, respectively.
In aqueous solutions, camptothecins are unstable and
undergo a rapid, pH-dependent, nonenzymatic hydro-
lysis of the terminal lactone ring to form the more
water-soluble, ring-opened carboxylate form (see
Structure).7 The presence of the intact terminal lactone
ring is thought to be essential for the topoisomerase I
inhibition.8 The closed lactone ring predominates at
acidic pH, whereas in human plasma the equilibrium
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between these 2 species greatly favors formation of the
carboxylate form, partly because of the physiologic pH
and the preferentially binding of this form to albu-
min.9,10 The ratio of the lactone form to the total drug
concentration at steady state in plasma is different for
each camptothecin analog, which might have important
pharmacokinetic and pharmacodynamic implications.
In preclinical studies 9-aminocamptothecin demon-
strated activity against human colon, breast, prostate, non-
small cell lung cancer, and melanoma xenografts.11-14
Preclinical in vivo data suggested that duration of expo-
sure to 9-aminocamptothecin lactone above a certain
threshold concentration (10 nmol/L) and frequency of
administration were essential for antitumor activity.15,16
Based on its preclinical activity, 9-aminocamp-
tothecin appeared to merit evaluation as an antineoplas-
tic agent. To mimic the preclinical studies, initial phase
I studies that used the intravenous formulation of 9-
aminocamptothecin focused on schedules with pro-
longed infusion duration of 24 to 120 hours17-21 or a
continuous infusion for 21 days every 4 weeks.22 Phar-
macokinetic data obtained during these studies showed
marked interpatient variability. Steady-state plasma con-
centrations of 9-aminocamptothecin lactone greater than
10 nmol/L were achieved only in the phase I study of
the 24-hour infusion of 9-aminocamptothecin at the
dose recommended for further phase II studies (ie, 1.65
mg/m2). When 9-aminocamptothecin was administered
as a 72-hour infusion once every 2 or 3 weeks, the max-
imal tolerated dose was 35 to 54.2 m g/m2/h. The dose-
limiting toxicity consisted of neutropenia in combina-
tion with thrombocytopenia and correlated to the steady-
state 9-aminocamptothecin lactone concentration.
We recently reported that 9-aminocamptothecin
demonstrated rapid absorption in humans after oral
delivery, with an overall bioavailability of approxi-
mately 50%.23 In the present report, we present a com-
prehensive analysis of the plasma pharmacokinetics of
the lactone and carboxylate forms of 9-aminocamp-
tothecin in patients with cancer receiving the drug
orally over a wide range of dose levels, with special
focus on pharmacokinetic-pharmacodynamic charac-
teristics. To assess the clinical usefulness of salivary
monitoring of 9-aminocamptothecin for kinetic model-
ing, paired plasma and coinciding unstimulated saliva
samples were collected in a limited number of patients.
PATIENTS AND METHODS
Patient population. Pharmacokinetic curves were
obtained from patients who participated in an oral
bioavailability study of 9-aminocamptothecin and/or in
a phase I trial of oral 9-aminocamptothecin adminis-
tered daily for 7 to 14 consecutive days every 3 weeks.
Treatment plans and detailed clinical profiles have been
documented elsewhere.23 Eligibility criteria included a
histologically or cytologically confirmed diagnosis of
a solid malignant tumor not amenable to established
forms of treatment. All patients had adequate
hematopoietic function (absolute peripheral granocyte
count ‡ 2.0 · 109/L and platelet count ‡ 100 · 109/L),
hepatic function (bilirubin within normal limits, and
serum aspartate aminotransferase, alanine aminotrans-
ferase, and alkaline phosphatase ≤2.5 times the normal
limit), and renal function (serum creatinine <133
m mol/L). Other eligibility criteria included the follow-
ing: age between 18 and 75 years, Eastern Cooperative
Oncology Group performance status ≤2, estimated life
expectancy ‡ 12 weeks, no previous anticancer therapy
for at least 4 weeks (6 weeks for nitrosourea or mito-
mycin), and no previous therapy with other camp-
tothecins or intensive ablative regimens. Specific exclu-
sion criteria included long-term treatment with corti-
costeroids and significant gastrointestinal dysfunction
that could alter absorption or motility. Concomitant
administration of H2-antagonists, antacids, proton-
pump inhibitors, and nonsteroidal anti-inflammatory
drugs were avoided. All patients gave written informed
consent before study entry.
Treatment plan and dose escalation. The oral formu-
lation of 9-aminocamptothecin was supplied by Pharma-
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Chemical structure and pH-dependent interconversion of 9-amino-20(S)-camptothecin lactone and
9-amino-20(S)-camptothecin carboxylate.
cia & Upjohn (Nerviano, Italy) as hard gelatin capsules
that contained 0.10, 0.25, or 1 mg of the active drug and
polyethylene glycol-1000 (PEG-1000) as excipient.23
The capsules were stored at room temperature.
A detailed description of the preparation and ratio-
nale for composition of the formulation has been
described previously.23 Patients received 9-aminocamp-
tothecin orally with 150 to 200 mL water at dose lev-
els of 0.25, 0.40, 0.60, 0.84, 1.0, or 1.1 mg/m2/day for
7 or 14 consecutive days or as a single dose of 1.5
mg/m2. Intrapatient dose escalation in the phase I trial
was not permitted. Weekly evaluation of the patients
included a clinical history, physical examination, toxi-
city assessment according to common toxicity criteria,
and serum chemistry. A complete blood cell count with
differentiation was determined twice weekly.
Sample collection and drug analysis. Serial blood
samples were collected in heparinized tubes from an
indwelling venous catheter at 0, 0.33, 0.67, 1, 1.5, 2, 3,
5, 7.5, 11, and 24 hours after administration on days 1
and 6 or days 1 and 8 of the first treatment course. In a
limited number of patients, unstimulated saliva sam-
ples were obtained at coinciding time points. In 1
patient with a malignant pleural effusion, additional
pleural fluid sampling was performed to assess the
influence of the pleural effusion on the plasma phar-
macokinetics. Immediately after sampling, aliquots of
plasma (separated at 4°C), pleural fluid, and saliva were
frozen at –80°C, and analyzed later for 9-aminocamp-
tothecin lactone and total 9-aminocamptothecin (ie, lac-
tone plus carboxylate) with use of a validated reversed-
phase HPLC method as described previously.24 Drug
concentrations in patient plasma samples were calcu-
lated with use of interpolation of the corresponding
regression analysis. Specimens with drug levels that
exceeded the upper range of the calibration curve were
reanalyzed after appropriate dilution with drug-free
plasma. Saliva and pleural fluid samples were diluted
4-fold in drug-free plasma and analyzed with use of the
same analytical assay, with minor modifications. The
lower limits of detection of the assays were 0.05 ng/mL
in plasma and 0.4 ng/mL in pleural fluid and saliva.
Data analysis. Plasma concentration data were ana-
lyzed with both noncompartmental and compartmental
analysis by use of the Siphar software package (version
4.0, Simed, Créteil, France). The model-independent
pharmacokinetic parameters included the maximum
plasma concentration and the time to reach maximum
plasma concentration. Initial parameter estimates were
obtained with use of an automated peeling algorithm
based on the Powell method to 3 compartments, which
yielded the best statistical fit as determined by the
Akaike information criterion and the F test. The area
under the plasma concentration–time curve (AUC) val-
ues were calculated on the basis of the best-fitted curve,
as were the disposition half-lives. The apparent absorp-
tion rate constant was obtained through numerical
point–area deconvolution. Relationships between the
AUC and pharmacodynamic outcome were evaluated
with (log-)linear and (non-)sigmoidal maximum effect
modeling by use of Siphar and NCSS version 5.0 (Dr
Jerry Hintze, East Kayesville, Utah). Within individual
patients, myelosuppression was described as the con-
tinuous variable, consisting of the percentage decrease
in white blood cell count, absolute neutrophil count,
and platelet count. The relative hematologic toxicity
was defined as follows:
% Decrease =
(Pretherapy value – Nadir value)/(Pretherapy value) · 100
Only the first course of each patient was taken into con-
sideration to avoid potentially confounding bias caused
by cumulative toxicity. All data were fitted to a sig-
moidal maximum effect (Emax) model based on the
modified Hill equation, as follows:
E = E0 + Emax · [(KPg )/(KPg + KP50g )]
In this equation, E0 is the minimum reduction possible
(fixed at a value of 0), Emax is the maximum response
(fixed at 100), KP is the pharmacokinetic parameter of
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Table I. Patient characteristics
No. of patients entered 32
No. of patients assessable for toxicity 30
Age (yr)
Median 59
Range 29-74
Sex (n)
Female 14
Male 16
Performance status
Median 1
Range 0-2
Tumor type (n)
Colorectal 14
Ovarian 5
Sarcoma 2
Mesothelioma 2
Lung (non-small cell) 2
Miscellaneous 5
Previous treatment (n)
Chemotherapy 16
Radiation 2
Chemotherapy and radiation 10
None 2
n, Number of patients.
interest, KP50 is the value of the pharmacokinetic para-
meter predicted to result in half of the maximum
response, and g is the Hill constant, which describes the
sigmoidicity of the curve. Models were evaluated for
goodness of fit by minimization of sums of the squared
residuals and by reduction of the estimated coefficient
of variation for fitted parameters. Significance of the
relationships were assessed by construction of contin-
gency tables with subsequent c 2 analysis.
RESULTS
Demographic characteristics of all 32 patients who
had blood sampling for pharmacokinetic analysis are
shown in Table I. Ten patients completed the oral
bioavailability study and subsequently participated in
the phase I and pharmacokinetic study of oral 9-
aminocamptothecin. Pharmacokinetic data were there-
fore obtained in 42 courses. Plasma pharmacokinetics
could not be determined in 1 course on day 1 and in 2
courses on day 8 as a result of limited sample availabil-
ity or significant chromatographic interference in the
drug assay by an unknown compound. Twenty-seven
patients were assessable for pharmacodynamic analy-
sis and 30 patients were assessable for toxicity.
The plasma concentration–time profiles of 9-
aminocamptothecin lactone and 9-aminocamptothecin
carboxylate were similar for all patients studied, with
representative examples shown in Figure 1. The phar-
macokinetics of both species of 9-aminocamptothecin
could be best described with a 3-compartment model.
The kinetic parameters obtained by means of this model
are presented in Tables II and III. The absorption of 9-
aminocamptothecin lactone after oral administration
was rapid, with a lag-time of 0.29 ± 0.07 hour (mean
± SD; n = 41), maximum peak drug levels at 0.99 ±
0.12 hour, and a mean absorption rate constant of 3.03
± 0.90 h-1. In the first plasma samples the ring-opened
carboxylate form of 9-aminocamptothecin was already
detectable. Maximal plasma concentrations of 9-
aminocamptothecin carboxylate were reached at 2.41
± 0.64 hours after administration. The 9-aminocamp-
tothecin carboxylate eventually accounted for 91.1% ±
2.11% of 9-aminocamptothecin total drug concentra-
tions, indicating a clear predominant conversion of lac-
tone to carboxylate. Elimination of 9-aminocamp-
tothecin from the central plasma compartment was
characterized by a decay in an apparent triexponential
manner based on conventional compartment modeling
with use of weighed least-squares analysis with a
weighting factor of 1/Y. The mean values for the linear
segments of 9-aminocamptothecin lactone were t1⁄2 a :
0.26 hour (range, 0.13 to 0.38 hour), t1⁄2 b : 0.78 hour
(range, 0.54 to 1.13 hours) and t1⁄2 g : 7.47 hours (range,
3.66 to 12.6 hours). No significant quantitative differ-
ences were observed between the decay kinetics of 9-
aminocamptothecin lactone and 9-aminocamptothecin
carboxylate.
The kinetic data and recorded AUC values for the
following days of administration were similar to those
achieved the first day in the same patient (Tables II and
III). Therefore the resulting intrapatient variability in
AUC and peak drug levels, expressed as the coefficient
of variation, was extremely small and averaged 8.67%
for 9-aminocamptothecin lactone and 10.9% for 9-
aminocamptothecin carboxylate. However, the interpa-
tient variability in the observed pharmacokinetics was
large, with coefficients of variation in AUC values as
high as 89.5% for 9-aminocamptothecin lactone and
99.0% for 9-aminocamptothecin carboxylate.
Over the total dose range studied, 9-aminocamp-
tothecin lactone and total 9-aminocamptothecin showed
linear and dose-independent pharmacokinetics (Figure
2, A and B, respectively). No significant relationship was
observed between the AUC values of total 9-aminocamp-
tothecin and that of the pharmacologically active species,
9-aminocamptothecin lactone (data not shown). The
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Figure 1. Representative concentration–time profiles of 9-
aminocamptothecin lactone (circles) and total 9-aminocamp-
tothecin (triangles) in plasma and in saliva (squares) mea-
sured on day 1 (open symbols) and day 8 (solid symbols) of
the first treatment course in a single patient after oral admin-
istration of 9-aminocamptothecin at a dose level of 0.84
mg/m2/day for 14 days. All pharmacokinetic curves were fit-
ted to a triexponential equation, assuming a 3-compartment
modal for the distribution and elimination of the drug.
interpatient variation in the equilibrium ratio of 9-
aminocamptothecin lactone and 9-aminocamptothecin
carboxylate could be explained in part by individual dif-
ferences in pretreatment serum albumin levels, for which
a significant correlation with the AUC ratio of 9-
aminocamptothecin lactone and 9-aminocamptothecin
carboxylate could be shown (r = 0.471, P = .0099). This
finding clearly indicates that separate monitoring of 9-
aminocamptothecin lactone and 9-aminocamptothecin
carboxylate concentrations is mandatory to relate drug
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Table III. Model-dependent pharmacokinetics of 9-AC carboxylate after oral administration of 9-AC
Dose (mg/m2/day)
0.25 0.40 0.60 0.84 1.0 1.1 1.5
n 6 3 4 6 7 3 12
tlag (h) 0.41 ± 0.20 0.34 ± 0.04 0.39 ± 0.13 0.31 ± 0.02 0.35 ± 0.15 0.34 ± 0.06 0.31 ± 0.11
tmax (h) 2.60 ± 1.19 2.20 ± 0.60 1.63 ± 0.23 2.01 ± 0.49 2.36 ± 1.19 3.67 ± 0.94 2.39 ± 1.05
Cmax (ng/mL) 9.43 ± 3.50 11.8 ± 5.76 14.5 ± 6.93 15.2 ± 4.88 25.5 ± 12.7 41.8 ± 19.6 35.4 ± 19.2
t1⁄2 a (h) 0.55 ± 0.50 0.40 ± 0.30 0.20 ± 0.20 0.18 ± 0.26 0.24 ± 0.38 0.96 ± 0.18 1.04 ± 0.78
t1⁄2 b (h) 1.78 ± 0.67 1.12 ± 0.44 1.00 ± 0.69 1.07 ± 0.55 0.78 ± 0.51 4.26 ± 1.60 2.83 ± 1.96
t1⁄2 g (h) 7.50 ± 3.96 6.59 ± 2.82 4.98 ± 1.74 9.61 ± 3.73 8.62 ± 3.57 10.1 ± 2.29 12.4 ± 6.48
AUC(0-∞), day 1 90.8 ± 48.2 89.0 ± 49.4 102 ± 45.1 174 ± 39.4 357 ± 265 578 ± 311 510 ± 354
(ng · h/mL)
AUC(0-∞), day 8 177 ± 127 137 ± 105 83.9 ± 34.1 162 ± 36.3 315 ± 327 592 ± 304 ND
(ng · h/mL)
Intrapatient 13.9 27.7 1.63 8.52 6.49 10.5 ND
%CV of AUC
Interpatient 53.1 55.5 44.3 22.6 99.0 53.9 69.4
%CV of AUC
Percent of total 92.8 ± 2.33 87.1 ± 4.20 91.2 ± 3.49 93.0 ± 1.72 89.8 ± 4.94 91.3 ± 3.22 92.7 ± 4.15
9-AC AUC
n, Number of patients; tlag, lag-time; tmax, time to peak plasma levels; Cmax, maximum plasma concentrations; t1⁄2(i), half-life of the ith disposition phase; AUC, area
under the plasma concentration versus time curve; CV, coefficient of variation; 9-AC, 9-amino-20(S)-camptothecin.
Table II. Model-dependent pharmacokinetics of 9-AC lactone after oral administration of 9-AC
Dose (mg/m2/day)
0.25 0.40 0.60 0.84 1.0 1.1 1.5
n 6 3 4 6 7 3 12
ka (L/h) ND ND ND ND ND ND 3.03 ± 0.90
tlag (h) 0.33 ± 0.13 0.32 ± 0.05 0.38 ± 0.14 0.28 ± 0.05 0.29 ± 0.05 0.17 ± 0.13 0.24 ± 0.13
tmax (h) 1.06 ± 0.35 0.79 ± 0.15 0.94 ± 0.11 0.98 ± 0.27 0.99 ± 0.29 1.00 ± 0.01 1.17 ± 0.33
Cmax (ng/mL) 2.09 ± 0.82 7.94 ± 7.39 3.43 ± 0.60 4.61 ± 1.51 11.0 ± 7.46 12.2 ± 6.95 6.82 ± 2.98
t1⁄2 a (h) 0.25 ± 0.20 0.13 ± 0.11 0.23 ± 0.07 0.24 ± 0.11 0.24 ± 0.09 0.36 ± 0.07 0.38 ± 0.21
t1⁄2 b (h) 0.68 ± 0.40 0.82 ± 0.33 0.54 ± 0.20 0.73 ± 0.33 0.76 ± 0.51 0.82 ± 0.16 1.13 ± 0.59
t1⁄2 g (h) 5.22 ± 4.22 8.65 ± 1.25 3.66 ± 0.55 10.3 ± 6.77 5.10 ± 2.68 6.76 ± 2.26 12.6 ± 4.20
AUC(0-∞), day 1 6.88 ± 4.76 16.2 ± 14.5 8.15 ± 0.76 12.9 ± 3.97 31.2 ± 19.1 49.3 ± 29.7 31.9 ± 14.3
(ng · h/mL)
AUC(0-∞), day 8 9.48 ± 3.85 17.4 ± 15.5 8.69 ± 0.70 11.7 ± 2.98 31.2 ± 27.0 48.5 ± 23.8 ND
(ng · h/mL)
Intrapatient 7.31 7.31 4.44 9.74 4.96 6.48 ND
%CV of AUC
Interpatient 69.2 89.5 89.2 30.7 61.1 60.3 44.8
%CV of AUC
Percent of total 7.18 ± 2.33 12.9 ± 4.20 8.76 ± 3.49 6.98 ± 1.72 10.2 ± 4.94 8.67 ± 3.22 7.30 ± 3.22
9-AC AUC
n, Number of patients; ka, absorption rate constant; tlag, lag-time; tmax, time to peak plasma levels; Cmax, maximum plasma concentrations; t1⁄2(i), half-life of the ith
disposition phase; AUC, area under the plasma concentration versus time curve; CV, coefficient of variation; 9-AC, 9-amino-20(S)-camptothecin.
levels to pharmacodynamic outcome in patients treated
with oral 9-aminocamptothecin.
Salivary drug monitoring was evaluated as an option
for determination of the AUC of 9-aminocamptothecin
lactone. The 9-aminocamptothecin lactone concentra-
tion ratio in plasma and unstimulated saliva was
strongly patient-dependent and highly variable around
a mean value of ~l.4, suggesting that saliva is an unre-
liable matrix for pharmacokinetic analysis of this drug
(Figure 1). To determine the impact of a pleural effu-
sion on the pharmacokinetics of 9-aminocamptothecin,
plasma and pleural effusion samples were obtained for
drug analysis in a single patient with a malignant
pleural effusion. The mean pleura versus plasma con-
centration ratio of 9-aminocamptothecin lactone was
4.95% ± 2.32 (mean ± SD; range, 0.7% to 6.8%). These
data indicate that pleural effusion does not constitute a
major pharmacokinetic compartment for this drug.
The pharmacokinetic data obtained from 27 patients
were plotted against the percentage decrease in white
blood cell count, platelet count, and absolute neutrophil
count at nadir relative to the pretreatment value. Four
different models, based on linear, log-linear, Emax, and
sigmoidal Emax fitting, were compared for their ability
to describe the data. With use of sigmoidal Emax mod-
eling of the pharmacokinetic and hematologic toxicity
data, significant correlations between the AUC of 9-
aminocamptothecin lactone and the percentage
decrease in white blood cell count (r = 0.86; P < .001;
Figure 3, A), the percentage decrease in platelet count
(r = 0.83; P < .001; Figure 3, B), and the percentage
decrease in absolute neutrophil count (r = 0.66; P <
.001; Figure 3, C) could be shown. In addition, the
worst observed myelotoxicity grade according to com-
mon toxicity criteria in the entire patient population
correlated with the AUC of 9-aminocamptothecin lac-
tone (r = 0.93; P < .001; data not shown). The devel-
opment of any myelotoxicity (grade 2 or worse) was
associated with an AUC of 9-aminocamptothecin lac-
tone ‡ 17.3 ng · h/mL, using the Hill equation and data
shown in Figure 2, B. Pharmacokinetic-pharmacody-
namic relationships based on (log-)linear and non-
sigmoidal Emax models were less predictive, as were
models based on 9-aminocamptothecin carboxylate or
total 9-aminocamptothecin (data not shown).
DISCUSSION
Topoisomerase I inhibitors are of great clinical inter-
est because of their unique mode of action, their impor-
tant antitumor activity, and the high expression of the
enzyme in various human tumor types. 9-Aminocamp-
tothecin, a semisynthetic analog of camptothecin,
revealed a broad antitumor activity in preclinical stud-
ies. Initial phase I studies focused on schedules with
prolonged infusion duration. An oral formulation was
developed to facilitate the prolonged drug administra-
tion. 9-Aminocamptothecin can be administered orally
as a colloid dispersion or as gelatin capsules in PEG-
1000. In dogs, the mean oral bioavailability of the col-
loid dispersion formulation was 13% (range, 4.5% to
26%), compared with 10% of the PEG-1000. Both for-
mulations retained their antitumor activity after oral
administration. The phase I study on the oral adminis-
tration of the colloid dispersion formulation of 9-
aminocamptothecin, 5 days per week every 2 weeks,
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Figure 2. Absolute dose of 9-aminocamptothecin plotted
versus area under the plasma concentration–time curve
(AUC) of 9-aminocamptothecin lactone (9-AClac; A) and total
9-aminocamptothecin (9-ACtot; B).
A
B
was recently completed.25 Diarrhea was the dose-
limiting toxicity at a dose level of 0.2 mg/m2.
9-Aminocamptothecin with PEG-1000 has been shown
previously to have rapid intestinal absorption in patients
after oral delivery, with an overall bioavailability (F)
of 48.6 ± 17.6%. This compares favorably to other
camptothecin analogs, including topotecan (F =
30.0%),26 7-(4-methyl-piperazinomethylene)10,11-eth-
ylenedioxy-20(S)-camptothecin (GI147211; F =
11.3%),27 and irinotecan (F = 12% to 21%).28 The ter-
minal half-life of 9-aminocamptothecin was shown to
be 12.6 to 4.20 hours, which is substantially longer than
that of topotecan (range, 2.35 to 5.91 hours)26 and
GI147211 (range, 6.85 to 3.13 hour).27 Another differ-
ence between topoisomerase I inhibitors constitutes the
AUC ratio of the active lactone and the total drug of the
parent drug. The conversion of 9-aminocamptothecin
lactone into the ring-opened species in plasma could be
shown from the first sample acquired (ie, at 0.33 hour).
At equilibrium, the 9-aminocamptothecin carboxylate
accounted for 91.1% ± 2.11% of 9-aminocamptothecin
total drug concentrations.
This compares unfavorably to the percentages present
in the ring-opened form at equilibrium observed in
patients for topotecan (~50%),26 GI147211 (~60%),27
and irinotecan and its active metabolite SN-38 (~65%
and ~35%, respectively).29 These figures underscore
the important differences in pharmacokinetics between
camptothecin analogs.
Our results of the phase I study with oral 9-
aminocamptothecin capsules indicated that the drug
could be administered in a 14-day schedule repeated
every 3 weeks with tolerable and manageable toxicity.30
The dose-limiting toxicities were a combination of
thrombocytopenia plus neutropenia complicated by
fever and diarrhea occurring at a dose level of 1.1
mg/m2/day. Other side effects were mild to moderate
(common toxicity criteria grade 1 to 2) and consisted of
nausea, vomiting, alopecia, mucositis, and fatigue.
Although 9-aminocamptothecin demonstrated a linear
pharmacokinetic behavior over the entire dose range
studied, we observed that the AUC of 9-aminocamp-
tothecin lactone was a better indicator for the observed
hematologic toxicity than the dose. The intrapatient vari-
ability in AUC and peak drug levels was extremely small
and averaged less than 10% for 9-aminocamptothecin
lactone. However, the interpatient variability in the con-
centrations of 9-aminocamptothecin at each of the sam-
ple time points, as well as in the AUC was large, with
values for the coefficient of variation as high as 99%.
In this study, the high variability in lactone to carboxy-
late interconversion was significantly related to individ-
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Figure 3. Correlation between the AUC of 9-aminocamp-
tothecin lactone and the percentage decrease in white blood
cells (WBC) at nadir of the first treatment course (A), in
platelets (PLC; B) and in neutrophils (ANC; C). The lines
represent the fitting of the data to a sigmoidal maximum-
effect model.
A
B
C
ual differences in pretreatment serum albumin levels.
Although our results need to be confirmed in a larger
number of patients, they tend to indicate that higher pro-
tein levels will result in a more profound binding of 9-
aminocamptothecin carboxylate, thereby further dimin-
ishing the effective concentration of the active species
of the drug. In all, these data indicate that classic drug
dosing based on body surface area alone is unlikely to
be effective in minimizing interpatient differences in
systemic exposure to oral 9-aminocamptothecin.
The pharmacokinetics of 9-aminocamptothecin were
clearly related to the pharmacodynamic outcome (ie,
hematologic toxicity). The sigmoidal Emax model was
most appropriate to fit the kinetic data to the observed
myelosuppression. The best correlation was obtained
with the AUC of 9-aminocamptothecin lactone, the
exposure to the active drug. Considering this pharma-
cokinetic-pharmacodynamic relationship, a target AUC
for 9-aminocamptothecin lactone can be defined accord-
ing to the grade of toxicity that is considered to be
acceptable in future studies. If hematologic toxicity
graded 2 or less is defined as acceptable, then the target
AUC of 9-aminocamptothecin lactone is 17.3 ng · h/mL,
using the Hill equation and data shown in Figure 2, A.
For pharmacokinetic and pharmacodynamic analysis
frequent blood sampling is inevitable. To evaluate sali-
vary drug monitoring of 9-aminocamptothecin as an
alternative to drug monitoring in plasma, the concen-
trations and AUC of 9-aminocamptothecin total and
lactone were measured in unstimulated saliva samples
in 5 patients during this study. The 9-aminocamp-
tothecin concentration ratio in plasma and unstimulated
saliva proved to be strongly patient-dependent and
highly variable, suggesting that saliva is an unreliable
matrix for pharmacokinetic analysis of 9-aminocamp-
tothecin. Similar results were obtained recently for
pharmacokinetic analysis of CPT-11 and SN-38 in
saliva demonstrating large interpatient variability in
plasma/saliva ratios.31
We recently developed a limited sampling model for
reliable and accurate prediction of the systemic expo-
sure to 9-aminocamptothecin after oral drug adminis-
tration, using only a 1-time blood sample taken 3 hours
after drug administration.32 To further diminish the
interpatient variability in drug exposure in future stud-
ies, a pharmacokinetic-guided approach may be con-
sidered. After oral administration of an appropriate
starting dose of 9-aminocamptothecin (ie, 1 mg/m2),
the 9-aminocamptothecin lactone plasma concentration
may then be measured at 3 hours after drug adminis-
tration. With use of the limited sampling model and the
linear-regression relationship between drug dose and
AUC (Figure 2), the optimal dose that leads to the tar-
get AUC (determined according to the toxicity consid-
ered to be acceptable) can be calculated.
This procedure may prove to be valuable in reducing
interpatient variation in exposure to 9-aminocamptothecin,
and it will enable us to optimize the treatment for any
given patient by combining maximally achievable doses
with tolerable toxicity during treatment. This strategy
seems to be interesting in both additional phase II studies
with the 14-day administration schedule and phase I stud-
ies with different schedules of administration. The clini-
cal applicability of this concept is currently under investi-
gation in our institute.
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